Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in Moderate to Severe Atopic Dermatitis
NCT03055195Phase 2Terminated
- Sponsor
- GSK
- Start
- Mar 2017
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Mepolizumab with Placebo (2 arms). Primary endpoint: Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 and at Least a 2- Grade Improvement at 16 weeks. Started Mar 2017; status: terminated.
02
Drugs
mepolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03055195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03055195.